Skip to main content
. 2021 Nov 28;27(44):7661–7668. doi: 10.3748/wjg.v27.i44.7661

Table 1.

Published studies of Helicobacter pylori eradication therapy in patients allergic to penicillin

Ref.
Yr
Country
Study type
Treatment details
n
Success rate (PP, %)
Success rate (ITT, %)
Prach et al[10] 1998 United Kingdom Prospective,single cohort 1st line O 20 mg b.d., C 500 mg t.d.s, 14 ds 3 100; 100;
Gisbert et al[11] 2005 Spain Prospective, single cohort 1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line RBC 400 mg b.d., T 500 mg q.d.s., M 250 mg q.d.s., 7 d; 3rd line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 4th line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 ds 12; 17; 9; 2 64; 53; 17; 100 58; 47; 11; 100
Rodriguez-Torres et al[12] 2005 Puerto Rico Prospective, single cohort 1st line E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d; 2nd line E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d 17; 3 NA; NA 85; 100
Matsushima et al[13] 2006 Japan Retrospective, single cohort 1st line PPI o.d., T 500 mg b.d., M 250 mg b.d., 7-14 d 5 100 80
Gisbert et al[14] 2010 Spain Prospective, single cohort 1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d 50; 15 55; 73 54; 73
Tay et al[15] 2012 Australia Prospective, single cohort 2nd line R 20 mg t.d.s., B 240 mg q.d.s., RIF 150 mg b.d., CF 500 mg b.d., 10 d 69 94.2 94.2
Liang et al[16] 2013 China Prospective, randomised 2nd line 109 pen allergic overall but results reported for whole group including non-allergic; L 30 mg b.d., B 220 mg b.d., T 500 mg t.d.s., F 100 mg t.d.s., 14 d; L 30 mg b.d., B 220 mg b.d., T 500 mg q.d.s., M 400 mg q.d.s., 14 d 108; 107 96.1; 93.1 91.7; 87.9
Furuta et al[17] 2014 Japan Retrospective, single cohort 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; 2nd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; 3rd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 3rd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d 7; 4; 9; 3; 3; 2 100; 100; 100; 100; 100; 100 100; 100; 100; 100; 100; 100
Gisbert et al[18] 2015 Spain Prospective, single cohort 1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 3rd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 4th line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 3rd line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 4th line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 3rd line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 1st line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d 112; 24; 3; 2; 7; 2; 50; 3; 50; 14 59; 38; 50; 0; 20; 100; 73; 100; 75; 64; 57; 37; 33; 50; 14; 100; 64; 100; 74; 64;
Mori et al[19] 2017 Japan Prospective, single cohort 1st line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; 2nd line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; 3rd line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d 33; 19; 5 100; 84.2; 40 100; 84.2; 40
Ono et al[20] 2017 Japan Retrospective,single cohort 1st line PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 1st line V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 1st line V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd line PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 2nd line V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 2nd line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd line V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d 10; 13; 20; 14; 3; 1; 24; 3 55.6; 92.3; 100; 100; 33.3; 100; 100; 66.7 50; 92.3; 100; 92.9; 33.3; 100; 100; 66.7
Sue et al[21] 2017 Japan Prospective& retrospective, single cohort 1st line V 20 mg b.d., C 200 or 400 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d, C 200 or 400 mg b.d, M 750 mg b.d., 7 d 20; 30 100; 86.2 100; 83.3
Osumi et al[22] 2017 Japan Prospective, single cohort 1st line R 20 mg b.d, Mi 100 mg b.d, M 250 mg b.d., 7 d 5 100 100
Long et al[23] 2018 China Prospective, randomised 1st line E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; 1st line E 20 mg b.d., B 600 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d 33; 33 70; 96 63.6; 84.8
Song et al[24] 2019 China Prospective, single cohort 1st line E 20 mg b.d, B 220 mg b.d., LF 500 mg o.d., Cef 500 mg b.d., 14 d 152 90.1 85.5
Nyssen et al[25] 2020 Europe Retrospective,multi-centre registry 1st line PPI, C, M; 1st line PPI, C, LF; 1st line PPI, B, T, M; 2nd line PPI, C, LF; 2nd line PPI, M, LF; 2nd line PPI, B, T, M; 3rd line PPI, B, T, M; 3rd line PPI, B, C, LF; 3rd line PPI, C, LF (NB drug dose, frequency and duration not specified) 285; 54; 250; 20; 13; 70; 18; 1; 2 69; 82; 92; 73.7; 76.5; 81.8; 77.8; 100; 50 69; 80; 91; 75; 76.5; 78.3; 77.8; 100; 50
Luo et al[26] 2020 China Prospective, single cohort 1st & 2nd line E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; 1st & 2nd line E20 mg b.d., B 220 mg b.d., C 500 mg b.d., M 400 mg q.d.s., 14 d; 1st & 2nd line E 20 mg b.d., LF 500 mg o.d., M 400 mg b.d., 14 d; 1st & 2nd line E 20 mg b.d., B 220 mg b.d, LF 500 mg o.d., M 400 mg q.d.s., 14 d; 1st & 2nd line E 20 mg b.d., T 500 mg q.d.s., M 400 mg b.d., 14 d; 1st & 2nd line E 20 mg b.d., B 220 mg b.d, T 500 mg q.d.s., M 400 mg q.d.s., 14 d 5; 22; 1; 10; 2; 72 100; 94.1; 100; 100; 100; 100 100; 81.8; 100; 80; 100; 97.2
Sue et al[27] 2021 Japan Prospective, single cohort 2nd line V 20 mg b.d,, SF 100 mg b.d., M 250 mg b.d., 7 d 17 88.2 88.2

PP: Per protocol analysis; ITT: Intention to treat analysis; B: Bismuth compound; C: Clarithromycin; Cef: Cefuroxime; CF: Ciprofloxacin; E: Esomeprazole F: Furazolidone; LF: Levofloxacin; M: Metronidazole; Mi: minocycline O: Omeprazole; PPI: proton pump inhibitor; R: Rabeprazole; RBC: ranitidine bismuth subcitrate; RIF: Rifabutin; SF: Sitafloxacin; T: Tetracycline; V: Vonoprazan.